ATS 2021: Nintedanib Effective in Long-Term Maintenance of Lung Function in Systemic Sclerosis-Associated Interstitial Lung Disease
Results were obtained from an open-label extension of the SENSCIS trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.